Drugs / DTP-HB-Hib vaccine
DTP-HB-Hib vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05155579 | May 2022 → May 2025 | malaria | University of Oxford | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02097472 | Apr 2014 → Dec 2015 | streptococcal pneumonia | PATH | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02409095 | Jan 2015 → Feb 2016 | — | Serum Institute of India Pvt. Ltd. | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00366678 Background | Oct 2006 → Nov 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-28 | Pfizer | U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents pfizer.com ↗ |
| 2022-09-15 | Pfizer | Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents pfizer.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTP-HB-Hib vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02409095 ↗ |
| Known as | Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate | “Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate” NCT02097472 ↗ |
| Known as | Pentavac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00366678 ↗ |
| Known as | Pentavalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05155579 ↗ |
| Modality | Vaccine | “active comparator vaccines (Synflorix and Pentavac)” NCT02097472 ↗ |
| Route | Intramuscular | “three deep intramuscular doses, 0.5 mL each dose 4 weeks apart” NCT02409095 ↗ |